These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 27372407)

  • 1. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
    Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
    Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer.
    Sadreddini S; Safaralizadeh R; Baradaran B; Aghebati-Maleki L; Hosseinpour-Feizi MA; Shanehbandi D; Jadidi-Niaragh F; Sadreddini S; Kafil HS; Younesi V; Yousefi M
    Immunol Lett; 2017 Jan; 181():79-86. PubMed ID: 27916629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line.
    Siahmansouri H; Somi MH; Babaloo Z; Baradaran B; Jadidi-Niaragh F; Atyabi F; Mohammadi H; Ahmadi M; Yousefi M
    J Pharm Pharmacol; 2016 Sep; 68(9):1119-30. PubMed ID: 27350211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SiRNA/DOX lodeded chitosan based nanoparticles: Development, Characterization and in vitro evaluation on A549 lung cancer cell line.
    Seifi-Najmi M; Hajivalili M; Safaralizadeh R; Sadreddini S; Esmaeili S; Razavi R; Ahmadi M; Mikaeili H; Baradaran B; Shams-Asenjan K; Yousefi M
    Cell Mol Biol (Noisy-le-grand); 2016 Sep; 62(11):87-94. PubMed ID: 27755958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
    Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
    Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line.
    Shali H; Shabani M; Pourgholi F; Hajivalili M; Aghebati-Maleki L; Jadidi-Niaragh F; Baradaran B; Movassaghpour Akbari AA; Younesi V; Yousefi M
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):293-302. PubMed ID: 28362176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy.
    Qian J; Xu M; Suo A; Xu W; Liu T; Liu X; Yao Y; Wang H
    Acta Biomater; 2015 Mar; 15():102-16. PubMed ID: 25545322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231).
    Eivazy P; Atyabi F; Jadidi-Niaragh F; Aghebati Maleki L; Miahipour A; Abdolalizadeh J; Yousefi M
    Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):889-896. PubMed ID: 27188536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of antiapoptotic genes in breast cancer cells by siRNA loaded into hybrid nanoparticles.
    de Mello LJ; Souza GR; Winter E; Silva AH; Pittella F; Creczynski-Pasa TB
    Nanotechnology; 2017 Apr; 28(17):175101. PubMed ID: 28230534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles.
    Yang F; Huang W; Li Y; Liu S; Jin M; Wang Y; Jia L; Gao Z
    Biomaterials; 2013 Jul; 34(22):5689-99. PubMed ID: 23632321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
    Afkham A; Aghebati-Maleki L; Siahmansouri H; Sadreddini S; Ahmadi M; Dolati S; Afkham NM; Akbarzadeh P; Jadidi-Niaragh F; Younesi V; Yousefi M
    Pharmacol Rep; 2018 Jun; 70(3):418-425. PubMed ID: 29626645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
    Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
    Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
    Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
    Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
    Naruphontjirakul P; Viravaidya-Pasuwat K
    Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
    [No Abstract]   [Full Text] [Related]  

  • 17. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
    Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
    Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.
    Zhuang J; Chen S; Hu Y; Yang F; Huo Q; Xie N
    Int J Nanomedicine; 2021; 16():1961-1976. PubMed ID: 33727809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
    Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
    Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.